Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1066 to 1080 of 1433 results for primary care

  1. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

    Medtech innovation briefing
    Published
    24 August 2016

  2. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of family therapy, psychodynamic psychotherapy and interpersonal psychotherapy for adolescents (IPT‑A) compared with each other and with individual CBT in young people aged 12 to 18 years with moderate to severe depression?

    life and suicidal ideas compared with waiting list/no treatment, or usual care. It also increased remission at the end of treatment...

    Research recommendation
    Published
    25 October 2019

  3. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    life and suicidal ideas compared with waiting list/no treatment, or usual care. It also increased remission at the end of treatment...

    Research recommendation
    Published
    25 October 2019

  4. Managing glioma: early referral to palliative care for glioblastoma:- Does early referral to palliative care improve outcomes for people with glioblastomas in comparison with standard oncology care?

    Managing glioma: early referral to palliative care for glioblastoma:- Does early referral to palliative care improve...

    Research recommendation
    Published
    11 December 2018

  5. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  6. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.

    NICE guideline
    Last updated
    7 November 2024
    View recommendations

    Sections for NG23

  7. Training in the use of the national quality standard and guidance on service user experience of care:- For people using adult mental health services, what is the effect of training community mental health teams (CMHTs) and inpatient ward staff in the use of the national quality standard and underpinning guidance on service user experience, when compared to no training, on service users' experience of care?

    the national quality standard and guidance on service user experience of care:- For people using adult mental health services, what is...

    Research recommendation
    Published
    9 June 2015

  8. Managing glioma: supportive care clinics for low-grade glioma:- Does a dedicated supportive care clinic in addition to standard care improve outcomes for people with low-grade gliomas?

    Managing glioma: supportive care clinics for low-grade glioma:- Does a dedicated supportive care clinic in addition to...

    Research recommendation
    Published
    11 December 2018

  9. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.

    Technology appraisal guidance
    Published
    25 September 2024

    Sections for TA1008

  10. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA298

  11. MI – secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction (CG48)

    This guidance has been updated and replaced by NICE guideline CG172.

    Clinical guideline
    Published
    23 May 2007

  12. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

    Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.

    Technology appraisal guidance
    Published
    5 October 2022
    View recommendations

    Sections for TA827

  13. Interim methods guide for developing service guidance 2014 (PMG8)

    This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance

  14. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

    Technology appraisal guidance
    Published
    21 November 2018
    View recommendations

    Sections for TA546

  15. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

    Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

    Technology appraisal guidance
    Published
    11 September 2024

    Sections for TA1005